All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Autobahn Therapeutics Inc. has closed a US$32.7 million financing to support the company's continued work in the treatment of central nervous system (CNS) disorders and the advancement of ABX-002 through phase I and into phase II proof-of-concept studies for treatment-resistant depression (TRD).